Vitrolife looks set for a rebound as delayed fertility treatment demand returns and the company keeps winning customers with newer tools and more automated lab workflows. But swings in exchange rates, legal costs, and uneven recovery in key markets could slow the comeback and pressure profits.Read more
Vitrolife sells tools and tests that help fertility clinics run IVF, and it could benefit as more clinics upgrade to automated lab systems and more patients opt for advanced embryo genetic testing. The upside case hinges on wider insurance coverage making IVF more accessible and on the company turning recent efficiency investments into steadier profits, while regional weakness and currency swings remain key wild cards.Read more
Catalysts About Vitrolife Vitrolife provides products and services used in IVF clinics, including media, disposable devices, lab technologies and genetic testing. What are the underlying business or industry changes driving this perspective?Read more
No trending discussion available.
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorporated in 1989 and is based in Gothenburg, Sweden.
